Reproductive health is a worldwide challenge, but it is of particular significance to women during their reproductive age. Several female reproductive problems, including
polycystic ovary syndrome (PCOS) and
endometriosis, affect about 10 % of women and have a negative impact on their health, fertility, and quality of life. Small, chemotactic, and secreted
cytokines are
CXC chemokines. Both PCOS and
endometriosis demonstrate dysregulation of
CXC chemokines, which are critical to the development and progression of both diseases. Recent research has shown that both in humans and animals,
CXC chemokines tend to cause
inflammation. It has also been found that
CXC chemokines are necessary for promoting angiogenesis and inflammatory responses.
CXC chemokine overexpression is frequently associated with poor survival and prognosis.
CXC chemokine levels in PCOS and
endometriosis patients impact their circumstances significantly. Hence,
CXC chemokines have significant potential as diagnostic and prognostic
biomarkers and therapeutic targets. The molecular mechanisms through which
CXC chemokines promote
inflammation and the development of PCOS and
endometriosis are currently unknown. This article will discuss the functions of
CXC chemokines in the promotion, development, and
therapy of PCOS and
endometriosis, as well as future research directions. The current state and future prospects of
CXC chemokine -based therapeutic strategies in the management of PCOS and
endometriosis are also highlighted.